A phase II safety and efficacy study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Bavituximab (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 27 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 27 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2010 New progression-free survival data will be presented at ASCO on June 5 2010 (Abstract no. 1042), as reported in a Peregrine Pharmaceuticals media release.